Tanruprubart

Phase 3Recruiting

1 views this week 0 watching⚡ Active🔬Featured in Small-Cap Pipeline Watch

Interest: 41/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Guillain-Barre Syndrome

Conditions

Guillain-Barre Syndrome

Trial Timeline

Sep 12, 2025 → Jun 30, 2028

NCT ID

NCT07020819

About Tanruprubart

Tanruprubart is a phase 3 stage product being developed by Annexon for Guillain-Barre Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07020819. Target conditions include Guillain-Barre Syndrome.

What happened to similar drugs?

0 of 1 similar drugs in Guillain-Barre Syndrome were approved

Approved (0) Terminated (0) Active (1)

🔄ANX005 + PlaceboAnnexonPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07020819	Phase 3	Recruiting	Sep 12, 2025	Jun 30, 2028	Guillain-Barre Syndrome

Competing Products

2 competing products in Guillain-Barre Syndrome

See all competitors

Product	Company	Stage	Hype Score
Efgartigimod Alfa-Fcab + Intravenous Immunoglobulin (IVIg)	Argenx	Phase 2	24
ANX005 + Placebo	Annexon	Phase 3	34